60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a
June 02, 2021 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021
May 21, 2021 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit
May 20, 2021 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 05, 2021 16:01 ET | Soleno Therapeutics
REDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome
May 04, 2021 08:00 ET | Soleno Therapeutics
Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR Data Presented in a Poster at the Pediatric Academic Societies Annual Meeting REDWOOD CITY, Calif., May 04,...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall
April 14, 2021 20:40 ET | Soleno Therapeutics
REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference
March 09, 2021 16:01 ET | Soleno Therapeutics
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
March 08, 2021 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
March 03, 2021 16:01 ET | Soleno Therapeutics
REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases
February 23, 2021 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...